Former Covidien Executive Joins Vesper Medical Board

Vesper Medical Inc., a developer of medical devices for deep venous disease, announced that Stacy Enxing Seng has joined the board of directors effective immediately.
 
An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. She currently serves as a venture partner for Lightstone Ventures and since 2013 has also focused her work on engaging as a professional director, serving as an independent director and committee member for both public and venture-backed private companies. In addition to serving on the Vesper Medical board, Seng currently serves a non-executive independent director for Hill-Rom Holdings Inc., Sonova Holding AG, and LivaNova Inc. She also chairs the Board of Directors at CALA Health, Contego, and is independent director for PreCARDIA, as well as a director for the Fogary Institute, a non-profit educational innovator.
 
“I am thrilled to join the Vesper board of directors. I have long had a passion for the importance of specifically designed and studied technology for peripheral vascular disease treatment,” stated Seng. “The Duo Venous Stent system and the VIVID Trial are clearly designed with the improvement of deep venous disease treatment in mind. I look forward to supporting Bruce and his team, as well as the Vesper Investors, to bring this important technology to the market.”
 
Over the course of her career, Seng has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions and served as the president of Covidien’s Vascular Therapies business following its acquisition of ev3, a medical technology start-up she co-created.

Seng earned a bachelor of arts degree in public policy from Michigan State University and an M.B.A. from Harvard University.
 
“Stacy brings a wealth of experience to our board of directors,” said Bruce Shook, Vesper Medical president and CEO. “Few executives in our industry can match her breadth and depth across large companies, entrepreneurial ventures and private equity investment. When you add to that her experience in the development of venous therapies, she is an ideal fit for Vesper Medical.”
 
The Vesper DUO Venous Stent System is a next-generation venous technology that advances the treatment of deep venous disease. Vesper Medical’s portfolio approach enables the clinician to tailor treatment in the iliofemoral venous anatomy based on disease patterns and severity. The DUO-HYBRID stent has a distinct integrated design that changes along its length from high crush resistance in the iliac region to high flexibility in the pelvic region, thus targeting the dynamic loading conditions in the iliofemoral venous system. The DUO-EXTEND stent is engineered to smoothly integrate with the DUO-HYBRID stent to provide physicians the flexibility to treat longer lesions.